BTI
ADVM

Blue Trust Inc’s Adverum Biotechnologies ADVM Stock Holding History

Blue Trust Inc’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-150
Closed -$2K – 2468
2023
Q3 		$2K Hold
150
– – ﹤0.01% 1790
2023
Q2 		$1K Hold
150
– – ﹤0.01% 1782
2023
Q1 		$1K Buy
+150
New +$1.06K ﹤0.01% 2084

Other funds holding ADVM

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Blue Trust Inc's ADVM Position: Q4 2023 in Review

Blue Trust Inc sold out of Adverum Biotechnologies (ADVM) in Q4 2023, closing a stake of 150 shares — an estimated $2K sold.

Blue Trust Inc first reported a position in ADVM in Q1 2023 and held it in 3 quarters. The position peaked at $2K in Q3 2023. 60 funds tracked by Wall St. Rank hold ADVM as of Q4 2023.

  • Blue Trust Inc reported no remaining Adverum Biotechnologies position as of Q4 2023 after selling out during the quarter.
  • Blue Trust Inc sold 150 Adverum Biotechnologies shares in Q4 2023, an estimated $2K.
  • Blue Trust Inc first reported a position in Adverum Biotechnologies in Q1 2023 and held it in 3 quarters.
  • Blue Trust Inc's Adverum Biotechnologies position peaked at $2K in Q3 2023.
  • 60 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2023.

Based on Blue Trust Inc's 13F filing for Q4 2023, filed 18 Jan 2024.